Vol. 5 No. 2 (2025): February
Reimbursement Reviews

Lebrikizumab (Ebglyss)

decorative image of the issue cover

Published February 11, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses lebrikizumab (Ebglyss) injection solution for SC injection, 250 mg/2 mL (prefilled pen or prefilled syringe with needle shield).
  • Indication: Lebrikizumab injection is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40 kg, whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Lebrikizumab can be used with or without topical corticosteroids.